CellTrend GmbH announced that it has forged a partnership with One Lambda Inc. Los Angeles, USA. This new alliance is part of a supply agreement, giving One Lambda worldwide exclusivity to distribute the Immuno-Assay product, EIA for Quantitative Determination of anti-Angiotensin II Receptor 1 (AT1)-Antibodies. This ELISA based application screens antibodies that form against Angiotensin II Type I Receptors (AT1R).
AT1R is involved in various neurohumoral systems and expressed on cells of several bodily organs, including the heart, liver, lungs, kidneys and others. Recent research studies have investigated the impact of non-HLA antibodies to AT1R in clinical outcomes of antibody-mediated rejection (AMR) in transplant patients. This observed association between high binding of antibodies to AT1R and AMR provides additional information that may be used to possibly determine immunological risk for organ transplant recipients. The AT1R Immuno-Assay can address the potential need for monitoring of non-HLA antibodies to AT1R.
This exclusive supply agreement will allow One Lambda (OLI) to maintain its mission and commitment to improving the quality of life for transplant patients and their families. CellTrend officials heralded this accord with great enthusiasm, announcing, “We are very proud to work with One Lambda! Together we can offer the AT1R Biomarker Assay worldwide and help to improve transplant graft survival”. In regards to this new opportunity OLI’s Director of Marketing, Stewart Han, expressed his gratitude saying, “One Lambda is delighted to have CellTrend part of their team and that the addition of the AT1R assay to the already comprehensive HLA antibody monitoring products, positions OLI at the forefront of transplant diagnostics.” OLI intends to launch the AT1R Immuno-assay in the third quarter of this year.
About CellTrend GmbH.
CellTrend GmbH is a biotechnology company that also works as a contract research organization for the pharmaceutical industry. CellTrend’s emphasis is formulating cell based bioassays with its focus in oncology and immunology. These developments include Immuno-Assays e.g. ELISAs, a quick and sensitive analytical method that is characterized by specific binding of antibodies to analytes. Additionally, CellTrend offer various validated diagnostic and research test kits. For more information, please visit www.celltrend.de.
About One Lambda Inc.
One Lambda, Inc. is the worldwide leader in HLA typing and antibody detection assays. One Lambda is known for its commitment to quality, service, and innovation. The company develops and distributes several lines of HLA typing and antibody detection tests utilizing serological, molecular, ELISA, flow, and Luminex xMAP technologies. In addition, One Lambda also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. For more information, please visit www.onelambda.com.
Further information can be obtained from:
CellTrend GmbH
Dr. Harald Heidecke, CEO
Im Biotechnologiepark, 14943 Luckenwalde.
Tel: +49 3371 681290 Fax: +49 3371 681312
E-Mail: info@celltrend.de
One Lambda, Inc., Stewart Han, Director of Marketing
21001 Kittridge Street Canoga Park, CA 91303.
Tel: 818-702-0042, Fax: 818-702-6904
E-mail: shan@onelambda.com